HuagongsheHuagongshe Chemistry Print Report · For research reference only
HRID 575367Generated: October 29, 2026
(R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one → HCID 86693410, compound
https://huagongshe.com/reaction/575367
Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | (R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one | HCID 86693296 | — |
| Reactant | HCID 86693411 | HCID 86693411 | — |
| Product | HCID 86693410 | HCID 86693410 | — |
Reaction Steps
Methyl 9-bromo-4-hydroxy-4,5-dihydro-[1]benzoxepino[5,4-d]thiazole-2-carboxylate was reacted similarly to as described in General Procedure P with non-critical modifications to afford 142 mg (94%) of methyl 9-bromo-4-fluoro-4,5-dihydro-[1]benzoxepino[5,4-d]thiazole-2-carboxylate. Methyl 9-bromo-4-fluoro-4,5-dihydro-[1]benzoxepino[5,4-d]thiazole-2-carboxylate was reacted with (3R)-3-ethynyl-3-hydroxy-1-methyl-pyrrolidin-2-one similarly to as described in General Procedure F with non-critical modifications to afford methyl 4-fluoro-9-[2-[(3R)-3-hydroxy-1-methyl-2-oxo-pyrrolidin-3-yl]ethynyl]-4,5-dihydro-[1]benzoxepin o[5,4-d]thiazole-2-carboxylate which was directed subjected to General Procedure M to afford 29 mg and 30 mg (37% overall yield) after reverse phase purification then chiral separation. The absolute stereochemistry at the 4-fluorine substitution position for each isomer was not determined.
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US09034866B2 |
|---|
| Source dataset | uspto-grants-2015_05 |
|---|
| ORD ID | ord-24a1b01f6237418dbc2b3d83fac59701 |
|---|
| Source note | uspto-grants-2015_05 |
|---|